# Yosemite

> Yosemite is an oncology-focused investment firm that combines venture investing, company creation, and philanthropic research grants. Launched independently from Emerson Collective in 2023 and led by Reed Jobs, it backs scientific research and businesses addressing cancer treatment, detection, and care delivery.

- **Founded:** 2023
- **Headquarters:** San Francisco, United States
- **Founders:** Reed Jobs (Founder and Managing Partner)
- **Products:** Oncology venture investment, Academic research support and company creation, Yosemite-American Cancer Society Award
- **Notable:** Established an independent oncology investment firm in 2023 after the team’s work at Emerson Collective., Co-launched the Yosemite-ACS program with a $13.2 million initial commitment in 2024., The inaugural Yosemite-ACS awards supported 20 projects with more than $6 million in grants in September 2024.

## Products & services

- **Oncology venture investment** — Equity financing for companies developing cancer therapeutics, diagnostics, digital health, and care delivery services.
- **Academic research support and company creation** — Philanthropic support for early scientific work alongside venture financing and help translating promising research into companies.
- **Yosemite-American Cancer Society Award** — Research grant program launched with an initial $13.2 million commitment. The 2025 call permitted up to $300,000 direct costs and $330,000 total costs for one- or two-year projects.

## Achievements

- Established an independent oncology investment firm in 2023 after the team’s work at Emerson Collective.
- Co-launched the Yosemite-ACS program with a $13.2 million initial commitment in 2024.
- The inaugural Yosemite-ACS awards supported 20 projects with more than $6 million in grants in September 2024.
- Supported academic research behind Azalea and participated in its $82 million combined seed and Series A financing announced November 2025.
- Co-led Daymark Health’s $11.5 million seed financing announced April 2025.

## Latest updates

- **2026-05** — Portfolio company Azalea announced non-human-primate data for its in vivo CAR T platform; the reported work was preclinical, not a demonstrated patient benefit.
- **2026-03** — The March 31 Form ADV record reported approximately $1.14 billion in regulatory assets under management. This adviser-wide measure is not a single fund’s size or revenue.
- **2026-03** — Investment head Dan McHugh discussed academic grants, company formation, and early-stage oncology investing on the Business of Biotech podcast.
- **2026-01** — Forbes reported a greater-than-$200 million first close toward a $350 million Fund II target. The separate January 29 Form D listed a $350 million proposed offering with no sales reported in that notice; its filing snapshot should not be treated as confirmation of the reported close.

## Links

- Website: https://www.yosemite.co/
- LinkedIn: https://www.linkedin.com/company/yosemiteco/

---

Profile page: https://yespress.io/yosemite
Published by YesPress — https://yespress.io
Last updated: 2026-10-27